We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

News   Apr 15, 2010

 
MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists
 
 
 

RELATED ARTICLES

Multigene Test Facilitates Targeted Use of Chemotherapy for Breast Cancer

News

New results show that the multigene test used at the university hospital in Munich is indeed helpful in making more targeted use of chemotherapy treatments and thus improves prognosis of breast cancer patients.

READ MORE

Fluidic Analytics Raises $31m to Launch Two New Products in Lab Tools Pipeline and Unlock Biology Behind Major Diseases

News

Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time.

READ MORE

Drug Combo Could Be More Effective Against Melanoma

News

A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE